BARNETT INTERNATIONAL ANNOUNCES EXPANSION OF CONSULTING MANAGEMENT TEAM
PHILADELPHIA, PA, February 15, 2001 — Barnett International, a division of PAREXEL International, LLC (Nasdaq: PRXL), announced today the expansion of its Consulting Management Team. Reflecting growth within Barnett International, the Management Team was established to guide the organization to its next level of achievement. Its members will develop and implement a long-term vision and strategic plan for the Consulting Group to further establish Barnett International as a provider of high-level consulting services to the healthcare industry. Barnett International is a recognized provider of pharmaceutical consulting, education and training, specializing in areas such as process improvement, organizational design, technological analysis, regulatory and quality assurance, clinical educational programs, industry conferences, and the publishing of drug development texts and journals.
Two seasoned consulting executives recently joined Barnett International’s Consulting Management Team; they are Robert Ketterer and John McCarthy. Bob and John will be working closely with three Barnett International veterans: Annette Horner, Stephanie Schwertz and Bob Zuercher.
Bob Ketterer comes to Barnett from Andersen Consulting, where he spent 5 years working with Top 5 pharmaceutical clients on projects that used his process design, re-engineering, and program management expertise in both regulatory and clinical environments. Prior to joining Andersen, Bob spent 2 years with KPMG Peat Marwick, where he primarily worked within the U.S. Navy’s Undersea Warfare Center developing, implementing and overseeing financial and management systems. Bob also spent 10 years working within the U.S. Army Aviation branch, designing organizational structures and re-engineering processes.
John McCarthy brings close to 10 years of pharmaceutical industry consulting experience to Barnett. Working for both Andersen Consulting and KPMG, John specialized in leading the design, development, and implementation of business and technology capability solutions within a number of major pharmaceutical companies. Prior to beginning his consulting career, John worked as a systems engineer for General Electric Management and Data Systems and Computer Task Group Inc.
Annette Horner, Ph.D., has 16 years of experience as a management consultant working with business and public-sector organizations on work process and design issues. Annette has been with Barnett International since 1986, and has focused for the past six years on clinical re-engineering implementation and other business process improvement efforts with Top 5 pharmaceutical clients. She has also consulted in the areas of clinical and regulatory performance improvement, process documentation, GCP implementation and compliance, and clinical training program design.
In her career as an industry consultant, Stephanie Schwertz has focused on change management consulting projects, specializing in strategic visioning and planning, facilitation, communications, training, process re-design, stakeholder management, change planning, career development, and organizational design and development for clinical and regulatory affairs organizations of leading pharmaceutical companies.
With more than 15 years of experience as a Barnett International consultant, Bob Zuercher has developed expertise in several key areas of clinical research. In his work with more than a dozen pharmaceutical companies in North America and Europe, Bob has helped clients develop implementation strategies for new clinical research systems, has analyzed and documented standard operating procedures for clinical research, and has designed and implemented programs for quality assurance and safety surveillance.
Barnett International has the benefit of being a division of PAREXEL International, one of the world’s leading providers of contract research services to the pharmaceutical, biotechnology, and medical device industries. In fact, PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its newest subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 47 locations throughout 29 countries around the world, and has approximately 4,350 employees.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended December 31, 2000.